Efficacy assessment for low-level laser therapy in the treatment of androgenetic alopecia: a real-world study on 1383 patients.
Lasers Med Sci
; 37(6): 2589-2594, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-35133519
ABSTRACT
Low-level laser therapy (LLLT) has been a treatment modality by many androgenetic alopecia (AGA) patients in recent years. It remained unclear as to how long the treatment regime should be maintained, and which characteristics of patients should this be recommended. A real-world study was carried out with an FDA-cleared low-level laser helmet for 1383 patients. Ordinal logistic regression analysis with propensity score matching (PSM) was used to investigate the factors related to efficacy assessment. More than 80% of users were between 18 and 40 years old. The median use times were 133 for mild AGA patients and 142 for moderate-to-severe AGA patients, which equated to 38 weeks and 40 weeks, respectively. The overall clinical effectiveness was nearly 80%. PSM analysis revealed that gender (P = 0.002), use period (P = 0.068), scalp conditions with dandruff, rash, and itchy symptoms were associated with the grading of efficacy assessment. Male users (ordinal OR 1.35, CI (1.01, 1.79)); use for more than 180 times or use period for 1 year (ordinal OR 1.40, CI (1.11, 1.96)); and those with scalp dandruff (ordinal OR 1.34, CI (1.01, 1.87)), rash (ordinal OR 1.47, CI (1.04, 2.07)), and itchy symptoms (ordinal OR 1.51, CI (1.12, 2.03)) had better efficacy assessments. The recommended treatment regime with low-level laser helmet was more than 1 year or 180 use times. Male patients with dandruff, rash, and itchy symptoms in scalps tended to have a better efficacy assessment.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Terapia com Luz de Baixa Intensidade
/
Exantema
/
Caspa
Limite:
Adolescent
/
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Lasers Med Sci
Assunto da revista:
BIOTECNOLOGIA
/
RADIOLOGIA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China